/ABOUT
Building the Next-Gen of Genetic Tools
THE Gene Weaver Technology Platform is a naturally derived programmable tool for controlled cutting and precision insertion of large genetic payloads.
Genetic medicines are driving a revolution in therapeutics
The enhanced gene editing/modification capability of the Gene Weaver Technology Platform is set to address the challenges facing the first generation of editing tools used to create the current genetic medicine pipelines across the industry. Current limitations include:
Off-target effects.
Restricted insertion capacity.
Cell cycle restricted
All of which limit the scope and applicability of these transformative therapies.
The Origin of Gene Weaver
The story of Gene Weaver begins with a drive to make complex biology beautifully simple.
For more than two decades, Dr Niall Armes has been transforming how molecular biology is done. At TwistDx, he pioneered Recombinase Polymerase Amplification (RPA), a breakthrough that made genetic detection portable, rapid, and accessible and is widely used inside many of today’s Next-generation sequencing technologies. Through BioCrucible and PartitionBio he has extended this philosophy to design biomolecular condensates to enable any biological cargo to be delivered to any cell type.
Building on this lead to him directing himself towards the next problem, making observation of their limitations he sought a solution.
That endeavour became Gene Weaver.
Gene Weaver is redefining how we can insert and control it. The company’s technology harnesses naturally derived, fully programmable insertion tools that can deliver large genetic cargos with high efficiency and precision, overcoming long-standing barriers in gene therapy and genome engineering.
By focusing on durable genetic medicines that are safe, predictable, and accessible to the widest patient populations, Gene Weaver extends Niall’s lifelong pursuit of practical innovation: turning the complexity of molecular biology into tools that truly serve human health.
At its heart, Gene Weaver is closing the loop between detection and creation, reading and writing, precision and purpose.
Meet the Minds Behind Gene Weaver.
-
Niall Armes
Founder & CEO
Niall Armes is the founder and CEO of Gene Weaver, driving the development of RNA-based, programmable genome engineering technologies. He leads the team in creating precise, safe, and highly efficient gene integration systems, harnessing AI to expand the possibilities of genetic medicine and bioengineering. Niall is passionate about translating cutting-edge science into real-world solutions for human health and agriculture. -
Helen Kent-Armes
Co-Founder & Director
Helen Kent-Armes is Co-Founder and Director of Gene Weaver, overseeing operations, organisational strategy, and team development. With a strong background in operations and HR, she ensures the company runs efficiently while fostering a collaborative, innovative culture. Helen is passionate about building high-performing teams that drive the development of safe and precise RNA-based genome engineering technologies. -
Glyn Baker
Chief Financial Officer
Glyn is an experienced finance leader with a strong track record of guiding high-growth biotech organisations through complex scaling, partnering, and commercialisation milestones. He joined Gene Weaver in 2025 as Chief Financial Officer, bringing deep expertise in financial strategy, capital allocation, and operational leadership across both early-stage and mature life-science companies. -
Frank Bowler
Principle Scientist
Frank is a highly skilled Principal Scientist at Gene Weaver, where he leads cutting-edge research into programmable gene insertion and precision gene repair. He brings deep expertise in molecular biology, DNA repair pathways, and functional genomics, helping to translate Gene Weaver’s next-generation platform into therapeutic-grade tools. With a passion for combining fundamental biology and engineering, Frank plays a central role in designing, validating, and optimising Gene Weaver’s gene-writing constructs and protocols. -
Ian Cook
Lead Scientist
Ian Cook brings over 15 years of experience in molecular biology, protein expression, purification, and cell biology to his role as Lead Scientist at Gene Weaver. He combines technical expertise with strong leadership skills, having managed senior scientific teams and guided complex projects from concept to execution. -
Simona Cugusi
Principal Scientist
Simona Cugusi brings deep expertise in transcriptional regulation and epigenetics to Gene Weaver. As a published molecular biologist, she has contributed to foundational work on transcription elongation dynamics, including elucidating roles in the heat-shock response -
Nicholas Dayrell-Armes
Scientific Researcher
Nicholas Dayrell-Armes is a Scientific Researcher at Gene Weaver, combining expertise in molecular biology, assay development, and a strong background in developing bioinformatic pipelines. -
Nikola Dzhindzhev
Principle Scientist
With extensive expertise in molecular biology, cell biology, and genetics, Nikola has previously performed ground-breaking research in the areas of cell division, cytoskeleton and centrosome biology. At Gene Weaver, Nikola applies his skill set to drive in vitro and in vivo assay development and implements innovative solutions to our versatile programmable gene-editing system on the way from the bench to real-life applications. -
Jessica Leigh
Research & Development Scientist
Jessica Leigh is a Research and Development Scientist at Gene Weaver, combining molecular and structural biology skills to contribute to the engineering of the company’s reprogrammable RNA-based genome editing technologies. An MSci Biochemistry graduate with research experience in both academic and industrial laboratories, Jessica brings a strong foundation in molecular biology and a passion for applying scientific innovation to real-world challenges. -
Chanakan Lorvoralak
Research & Development Scientist
Chanakan is an R&D Scientist at Gene Weaver with a background in Biomedical Science and expertise in molecular biology, enzymology, and protein biochemistry. His research experience spans cataract formation, iron metabolism, and neurodegenerative disease, with a focus on translating molecular insight into human benefit. -
Caroline Orros
Operations & Finance Manager
Caroline Orros is the Finance and Operations Manager at Gene Weaver, where she oversees the company’s financial management, operational efficiency, and administrative strategy. With over a decade of experience in finance and business operations, Caroline has held key roles across technology and biotechnology organisations including BioFaze, Linx Printing Technologies, ANSYS, and Mott MacDonald. Her background spans bookkeeping, accounts management, and organisational administration, bringing structure and precision to fast-paced, innovative environments. -
Craig Smith
Senior Marketing Manager
Craig Smith is the Senior Marketing Manager at Gene Weaver, bringing over a decade of experience in marketing, design, and brand strategy. He combines creativity with analytical insight to craft digital campaigns and visual narratives that connect complex science with clear, engaging storytelling. With a background spanning digital marketing, UX design, and data-led brand development, Craig has led initiatives that elevate visibility, enhance user experience, and drive growth across innovative biotech and technology ventures. -
Sara Toral-Perez
Scientist
Sara is a Scientist at Gene Weaver, working in cell and molecular biology to develop, test, and validate next-generation genome engineering technologies in mammalian cell culture. She holds a PhD in Biomedical Sciences and experience across academic and industry-collaborative research. Her background includes mammalian cell culture and molecular biology, complemented by experience in genomic and transcriptomic data analysis, human tissue–based pharmacological studies, and high-resolution microscopy with AI-assisted analysis. -
Jonathan Ward
Lead Informatics Scientist
Jonathan drives the informatics vision at Gene Weaver, building and maintaining the pipelines and software that power integrative functional-genomics workflows. With a strong background in data science, computational biology, and large-scale data integration, he ensures that Gene Weaver’s platform can scale to handle heterogeneous genomic datasets with speed and rigor. He’s passionate about translating raw data into biological insight, enabling researchers to uncover gene-set relationships and functional signatures across species.
